Sarepta Therapeutics CSO Louise Rodino-Klapac's 2021 pay rises 17% to $8.5M
Sarepta Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 25, 2022
Sarepta Therapeutics reported fiscal year 2021 executive compensation information on April 25, 2022.
In 2021, five executives at Sarepta Therapeutics received on average a compensation package of $5.1M, a 44% increase compared to previous year.
Average pay of disclosed executives at Sarepta Therapeutics
Louise Rodino-Klapac, Chief Scientific Officer, received $8.5M in total, which increased by 17% compared to 2020. 54% of Rodino-Klapac's compensation, or $4.6M, was in stock awards. Rodino-Klapac also received $360K in non-equity incentive plan, $3M in option awards, $556K in salary, as well as $14K in other compensation.
For fiscal year 2021, the median employee pay was $271,908 at Sarepta Therapeutics. Therefore, the ratio of Louise Rodino-Klapac's pay to the median employee pay was 31 to one.
Ian M. Estepan, Chief Financial Officer, received a compensation package of $5.1M, which decreased by 1% compared to previous year. 58% of the compensation package, or $3M, was in option awards.
Ryan Brown, General Counsel, earned $5.1M in 2021.
William Ciambrone, Executive Vice President, Technical Operations, received $5M in 2021, which increases by 642% compared to 2020.
Douglas Ingram, Chief Executive Officer, earned $1.5M in 2021, a 20% increase compared to previous year.
Related executives
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
Ian Estepan
Sarepta Therapeutics
Chief Financial Officer
Louise Rodino-Klapac
Sarepta Therapeutics
Chief Scientific Officer
William Ciambrone
Sarepta Therapeutics
Executive Vice President, Technical Operations
Ryan Brown
Sarepta Therapeutics
General Counsel
You may also like
Source: SEC filing on April 25, 2022.